EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Next‐Generation CAR‐T Cell Therapy: From Modular Design to Clinical Expansion

Yuesong Bai, Jintao Qin, Zongjun Dai, Ran Yan, Yong Yang, Wenguang Wang

Exploration · 2026-10 · 6 (5)

DOI: 10.1002/exp2.70230 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Exploration, online erschienen am 21.10.2026. Verfasst von Yuesong Bai und 5 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Translational Medicine China Pharmaceutical University Nanjing China. Die Arbeit nennt 310 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, China Pharmaceutical University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chimeric antigen receptor (CAR)‐T cell therapy has emerged as a groundbreaking treatment for cancer. After decades of research, it is now being actively explored for a broader range of immune‐mediated diseases, particularly cancer and autoimmune disorders. Significant progress has been made in both understanding technological advancements and addressing the intrinsic limitations of this engineered cellular therapy. However, the clinical efficacy and safety of CAR‐T cells remain influenced by several factors, including the immunosuppressive tumour microenvironment (TME), the continuous mutational evolution of tumour cells, the prohibitive cost of production limiting accessibility, and the immune‐related toxicities associated with biologic treatments. Given these substantial challenges, a paradigm shift is urgently needed – from conceptualizing CAR‐T cells solely as “engineered immune cells” to recognizing them as “programmable intelligent systems.” This review proposes a dynamic immune engineering framework, advocating that the next generation of CAR‐T cells be conceived as programmable immune systems capable of sensing, responding to, and self‐regulating immune responses. This evolving approach positions dynamic immune regulation as the core principle underlying immune system function. Ultimately, this review aims to provide a conceptual and theoretical foundation for the development of next‐generation CAR‐T therapies that are not only highly effective but also cost‐efficient and globally accessible.

Schlagwörter

Stichwörter der Autor:innen

CAR‐T cell therapyautoimmune disorderscancerdynamic immune engineering

Autor:innen und Institutionen

  • Institute of Translational Medicine China Pharmaceutical University Nanjing China.
  • Center for New Drug Safety Evaluation and Research China Pharmaceutical University Nanjing China.
  • School of Biopharmacy China Pharmaceutical University Nanjing China.
  • Key Laboratory of Biomedical Functional Materials School of Science China Pharmaceutical University Nanjing China.

Förderung

  • National Natural Science Foundation of China
  • China Pharmaceutical University

Zitieren

APA

Bai, Y., Qin, J., Dai, Z., Yan, R., Yang, Y., & Wang, W. (2026). Next‐Generation CAR‐T Cell Therapy: From Modular Design to Clinical Expansion. Exploration, 6(5). https://doi.org/10.1002/exp2.70230

Vancouver

Bai Y, Qin J, Dai Z, Yan R, Yang Y, Wang W. Next‐Generation CAR‐T Cell Therapy: From Modular Design to Clinical Expansion. Exploration. 2026;6(5). doi:10.1002/exp2.70230

BibTeX
@article{Bai2026,
  author = {Bai, Yuesong and Qin, Jintao and Dai, Zongjun and Yan, Ran and Yang, Yong and Wang, Wenguang},
  title = {Next‐Generation CAR‐T Cell Therapy: From Modular Design to Clinical Expansion},
  journal = {Exploration},
  year = {2026},
  volume = {6},
  number = {5},
  doi = {10.1002/exp2.70230}
}
Kostenlos starten →